Bloomberg BNA’s BioTech Watch is a daily bulletin offers comprehensive regulatory and legal coverage of biotechnology...
By W. Randy Kubetin
Nov. 25 — Amgen Inc. announced Nov. 25 that it has submitted a biologics license application to the FDA for ABP 501, a biosimilar of AbbVie's top-selling arthritis drug Humira (adalimumab).
Amgen said it believes this is the first adalimumab biosimilar application submitted to the Food and Drug Administration, and noted that it's Amgen's first BLA submission using the Section 351(k) biosimilar approval pathway under the Biologics Price Competition and Innovation Act.
“The submission of Amgen's first biosimilar application to the FDA is an exciting milestone, expanding our inflammation portfolio to provide additional therapeutic options to patients,” Sean E. Harper, executive vice president of research and development at Amgen, said in a statement.
Adalimumab is an anti-TNF-α monoclonal antibody approved in many countries for treating various inflammatory diseases. Humira is AbbVie's top-selling drug, with estimated 2015 sales of $14 billion, according to Bloomberg data.
Amgen said its BLA submission includes analytical, clinical and pharmacokinetic data. Phase III comparative efficacy and safety studies were conducted in both moderate-to-severe plaque psoriasis and moderate-to-severe rheumatoid arthritis. The phase III studies met their primary endpoints showing clinical equivalence to adalimumab, Amgen said, and safety and immunogenicity of ABP 501 were also comparable to adalimumab.
The active ingredient of ABP 501 is an anti-TNF-α monoclonal antibody that has the same amino acid sequence as adalimumab, Amgen said. ABP 501 has the same pharmaceutical dosage form and strength as adalimumab (U.S.) and adalimumab (EU), the company said.
According to the FDA, a biosimilar product is a biological product that is approved based on a showing that it is highly similar to an already-approved biological product, known as a reference product. In March, the FDA approved the first biosimilar in the U.S. That biosimilar product is Zarxio, a Sandoz biosimilar of an Amgen reference product, Neupogen (filgrastim).
To contact the reporter on this story: W. Randy Kubetin in Washington at email@example.com
To contact the editor responsible for this story: Lee Barnes at firstname.lastname@example.org
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)